

Evaluation Report for Category B, Subcategory 1.1 Application

Application Number: 2023-0494

Application: Changes to End-use Product (Product Chemistry) – New

Formulation (Site) Same Registrant

Product: Trunemco **Registration Number:** 34519

Active ingredients (a.i.): Bacillus amyloliquefaciens strain MBI600 and cis-Jasmone

PMRA Document Number: 3462124

Purpose of Application

The purpose of this application was to add a new formulating site for the commercial class enduse product Trunemco.

Chemistry Assessment

Trunemco is formulated as a suspension containing *Bacillus amyloliquefaciens* strain MBI600 at not less than 2.0×10^9 CFU/ mL and *cis*-Jasmone at a concentration of 0.88%. This end-use product has a density of 1.02 - 1.07 g/cm³ and pH of 6.0 - 7.5. The chemistry requirements for this product have been fulfilled.

Product Characterization and Analysis

The data submitted to assess the additional formulating site were acceptable.

Health, Environmental and Value Assessments

Health, environmental and value assessments were not required for this application.

Conclusion

The Pest Management Regulatory Agency has completed an assessment of the information provided, and has found the information acceptable to support the addition of a new formulating site for Trunemco.

References

PMRA	Reference
Document	
Number	
3433117	2023, A Five-Batch Potency Analysis of Trunemco Formulated at a New Site, DACO: M2.10.1 CBI
3433118	2022, Trunemco Formulation Process, DACO: 3.2.1,3.2.2 CBI
3454237	2023, Trunemco_Def Response Letter_230417, DACO: M2.10.1



2020, M0026-04 Method for the Quantitative Determination of MBI600 in 3454238 Microbial Biological Pesticide Technical Grade Products, End-Use Products, and Coated Seeds, DACO: M2.10.1 © His Majesty the King in Right of Canada, as represented by the Minister of Health Canada, 2023

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written

permission of Health Canada, Ottawa, Ontario K1A 0K9.